Registration for a live webinar on 'Neuroleptic malignant syndrome' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Key questions
- What are therapeutic antibodies?
- The therpeutic antibody market
- Market analysis
- Drug development funnel
- Naming conventions
- Identifying and optimizing potential therapeutic antibodies
- Antibody drug development
- Options for therapeutic mAb development
- Options A and C: mouse hybridoma technology
- Option B: phage display
- Option D: single cell sorting of human B cells
- Antibody modifications for better performance
- Conclusions
- Thank you
Topics Covered
- Therapeutic antibodies
- Therapeutic antibody market
- Antibodies nomenclature
- Options for therapeutic antibody development
- Antibody modifications
Links
Series:
Categories:
External Links
Talk Citation
Hanack, K. (2022, September 29). Therapeutic antibody development [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved October 11, 2024, from https://doi.org/10.69645/DPLJ3048.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Dr. Katja Hanack has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Other Talks in the Series: Periodic Reports: Advances in Clinical Interventions and Research Platforms
Transcript
Please wait while the transcript is being prepared...
0:00
Hello, I'm Katja Hanack,
Professor of Immunotechnology at
the University of
Potsdam in Germany.
Today I'm going to talk
about antibody discovery,
especially, therapeutic
antibody development.
0:14
Within the next minutes,
I would like to talk
about the main questions,
what are therapeutic antibodies?
What does it mean to generate
therapeutic antibodies?
How is the generation
process done in general?
Also, what are the
challenges when using
these antibodies as a
therapeutic treatment?
0:36
What is meant by the term
therapeutic antibodies?
Antibodies in general
are induced in vivo
as part of our adaptive
immune response
and after infection
with pathogens,
so-called antigen-presenting
cells are processing
and presenting part of the
pathogen to T and B cells.
This induces an activation
cascade where T cells
are differentiated into
effector and helper cells
secreting cytokines which
could act in different ways.
For antibody generation,
the immune response
is based on two
important signals.
One signal is the induction
of T helper cells,
which secrete B
cells and cytokines,
such as IL-4, IL-5, or 13.
The B cell is just
recognizing the pathogen with
the corresponding B cell
receptor on the cell surface.
A third situation is present.
The B cell gets a specific
activation signal to start
with the maturation and release
of the B cell receptor,
and the soluble B cell receptor
is called an antibody,
and is part of the
humoral immune response.
Antibodies are highly specific
for their corresponding antigen
and are therefore of high
interest for research,
diagnostics, and
therapeutic applications.
The spectrum of using
antibodies is manyfold.
In general, it is possible to
induce specific antibodies
against all given structures;
on cells, bacteria,
viruses, and also again,
on soluble components,
such as proteins, hormones,
toxins or nucleic acids.
These variable properties
allow mammalians to possess
possess a highly sophisticated
and adaptable system
to react against all
types of pathogens
and disease conditions.
The body is producing a
diverse antibody repertoire
against different diseases
and protects the body
against pathogens.
To use this capability
for the generation of
customized antibody
formats in vitro is,
of course, of high interest
for biomedical applications.